LB Pharmaceuticals Launches Phase III Trial of LB‑102, Targeting Unmet Schizophrenia Symptoms
LB Pharmaceuticals’ Phase‑III trial of LB‑102 aims to transform schizophrenia care by tackling unmet negative and cognitive symptoms, offering hope for next‑generation treatment.
3 minutes to read